
Handbook of Experimental Pharmacology

Volume 249

Editor-in-Chief

J.E. Barrett, Philadelphia

Editorial Board

V. Flockerzi, Homburg

M.A. Frohman, Stony Brook, NY

P. Geppetti, Florence

F.B. Hofmann, München

M.C. Michel, Mainz

C.P. Page, London

W. Rosenthal, Jena

K. Wang, Qingdao

More information about this series at <http://www.springer.com/series/164>

Mario Mandalà • Emanuela Romano
Editors

Mechanisms of Drug Resistance in Cancer Therapy

Editors

Mario Mandalà
Department of Oncology and Hematology
Papa Giovanni XXIII Hospital
Bergamo, Italy

Emanuela Romano
Department of Oncology, INSERM Res
Unit 932
Institut Curie
Paris Cedex 05, France

ISSN 0171-2004

ISSN 1865-0325 (electronic)

Handbook of Experimental Pharmacology

ISBN 978-3-030-10506-8

ISBN 978-3-030-10507-5 (eBook)

<https://doi.org/10.1007/978-3-030-10507-5>

Library of Congress Control Number: 2018966536

© Springer Nature Switzerland AG 2018

This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG
The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Preface

The remarkable advances in precision medicine and the development of targeted cancer treatments have generated significant optimism based on the assumption that a better knowledge of genetic or molecular features sustaining cancer growth could determine long-term control of many types of cancer and potentially cure the majority of patients. After several years of basic and translational research, the oncology community has tempered this optimism by the recognition that in only a minority of patients cure can be achieved by innovative strategies such as targeted therapies, immunotherapy and cytotoxic agents. In the vast majority of cancer patients, cancer wins the battle, and the reason for this failure is drug resistance. Ultimately, advanced cancer patients die because some or all of their tumour cells exhibit or develop resistance to available therapeutic strategies. The challenge of drug resistance therefore represents an important barrier that hinders the ultimate goal of cure or at least long-term control of cancer.

As a corollary of this, response rates in the setting of tumour progression/relapse are dismal. Despite the considerable importance of drug resistance to cancer therapies, our understanding of their biological mechanisms – and plausible therapeutic avenues to intercept them – remains highly incomplete.

Knowledge of specific resistance mechanisms can inform novel therapeutic approaches to counter this phenomenon, and improvement of our understanding of key driver genes could guide new therapeutics approaches capable of eliciting meaningful tumour responses in patients with advanced malignancies.

As previously reported with chemotherapy, it is reasonable to suppose that a combination of multiple targeted therapies and immunotherapy strategies as well as planned sequence of treatments will be necessary to effectively prevent and/or treat drug-resistant cancers. The potential number of therapeutic combinations is immense; thus, new preclinical paradigms are needed to prioritize high-yield combinations and define the genetic or molecular contexts in which they would most likely be efficacious. To improve outcome of patients a strict collaboration between academia and industry will be needed so that the appropriate resources and innovation may be brought to bear on this challenge. The goal to achieve durable control of many cancer subtypes will likely require dedicated, multidisciplinary teams of preclinical and clinical experts that work together guided by rigorous translational and analytical science.

With the increasing armamentarium of anticancer agents and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clinical assessment of rational therapeutic drug combinations and the use of predictive and prognostic biomarkers to enable patient stratification and tailor treatments.

The main aim of this book is to offer to the readers an updated overview on the possible reasons of failure of new and promising therapeutic opportunities.

The first part of the book covers the basic mechanisms of such hot topics. The other chapters cover specific pathways of resistance that from the knowledge of basic mechanisms translate this information in clinical routine or in translational clinical research.

Readers will discover diverse perspectives of the contributing authors (such as basic scientists, clinical pharmacologists and clinicians) and extensive discussions of issues including pharmacodynamic and pharmacokinetic mechanisms of resistance, alterations in the drug target, activation of prosurvival pathways, ineffective induction of cell death and plasticity of microenvironment.

This book will be of interest to scholars and researchers, biologists, pharmacologists, medical oncologists, haematologists and immunologists.

Bergamo, Italy
Paris Cedex 05, France

Mario Mandalà
Emanuela Romano

Contents

Molecular and Pharmacological Mechanisms of Drug Resistance: An Evolving Paradigm	1
Benedetta Colmegna, Lavinia Morosi, and Maurizio D’Incalci	
Major Physiological Signaling Pathways in the Regulation of Cell Proliferation and Survival	13
Huifang Tang and Gongda Xue	
Immune-Mediated and Hypoxia-Regulated Programs: Accomplices in Resistance to Anti-angiogenic Therapies	31
Diego O. Croci, Santiago P. Mendez-Huergo, Juan P. Cerliani, and Gabriel A. Rabinovich	
Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer	63
Francesco Facchinetti, Claudia Proto, Roberta Minari, Marina Garassino, and Marcello Tiseo	
Mechanisms of Drug Resistance in Melanoma	91
Matthew Winder and Amaya Virós	
Mechanisms of Resistance to Immune Checkpoint Antibodies	109
Rodrigo N. Ramos, Eliane Piaggio, and Emanuela Romano	
Immunotolerance as a Mechanism of Resistance to Targeted Therapies in Melanoma	129
Mario Mandalà and Daniela Massi	
Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer	145
Andrea Sartore-Bianchi and Salvatore Siena	
Targeting DNA Repair	161
Giuseppe Curigliano	
Resistance to Hormonal Therapy in Prostate Cancer	181
Alfredo Berruti and Alberto Dalla Volta	

Mechanism of Resistance in Gastrointestinal Stromal Tumors	195
E. Tamborini	
Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia	203
Francesca Arruga and Silvia Deaglio	
Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia	231
Federico Lussana, Tamara Intermesoli, Paola Stefanoni, and Alessandro Rambaldi	
Mechanisms of Resistance in Multiple Myeloma	251
Athanasios Papadas and Fotis Asimakopoulos	
Cancer Evolution as the New Frontier of Precision Medicine	289
Giuseppe Curigliano	